I've always thought it would settle out to $15-$20 just based on COVID approval. Uplisting could add another $2-$5 based on institutional activity. If larger investors actually do the research on the science and realize the potential then it should start creeping up even before HIV approval and cancer results. Of course once results from other trials start coming in is when you'll see more substantial price gains.

But I do tend to stay conservative on price.